Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 11/20 | 0.69 |
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
| ▸ | DRD4 | P21917 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.63 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20985478 | 0.99 | GRIN2B (0.67) | GRIN2BDRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL7272848 | 0.92 | DRD2 (0.60) | GRIN2BDRD2DRD4DRD3SIGMAR1 | |
| Bromide SCHEMBL7281378 | 0.91 | DRD2 (0.59) | GRIN2BDRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL11075369 | 0.90 | DRD2 (0.70) | GRIN2BDRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL7329677 | 0.86 | GRIN2B (0.69) | GRIN2BDRD2DRD3SIGMAR1GRIN1 | |
| Hydrochloric Acid SCHEMBL7326858 | 0.85 | GRIN2B (0.67) | GRIN2BDRD2DRD3SIGMAR1GRIN1 | |
| Hydrochloric Acid SCHEMBL7334760 | 0.85 | GRIN2B (0.67) | GRIN2BDRD2DRD3SIGMAR1GRIN1 | |
| Hydrochloric Acid SCHEMBL7329362 | 0.85 | GRIN2B (0.67) | GRIN2BDRD2DRD3SIGMAR1GRIN1 | |
| Hydrochloric Acid SCHEMBL7337819 | 0.85 | GRIN2B (0.67) | GRIN2BDRD2DRD3SIGMAR1GRIN1 | |
| Hydrochloric Acid SCHEMBL7333173 | 0.85 | GRIN2B (0.67) | GRIN2BDRD2DRD3SIGMAR1GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4717276-A2 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | University of Canberra (AU) | 2026-04-01 | — | — | EP | claimed |
| EP-3442516-B1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIV CANBERRA (AU) | 2025-11-12 | — | — | EP | claimed |
| US-11890266-B2 | Ophthalmic compositions including levodopa, an antioxidant and an aqueous carrier | UNIVERSITY OF CANBERRA (AU) | 2024-02-06 | — | — | US | claimed |
| US-20220047529-A1 | METHODS OF INHIBITION | UNIVERSITY OF CANBERRA (AU) | 2022-02-17 | — | — | US | claimed |
| US-20210077443-A1 | OPHTHALMIC COMPOSITIONS INCLUDING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIVERSITY OF CANBERRA (AU) | 2021-03-18 | — | — | US | claimed |
| US-10874629-B2 | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | UNIVERSITY OF CANBERRA (AU) | 2020-12-29 | — | — | US | claimed |
| US-20190151270-A1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIVERSITY OF CANBERRA (AU) | 2019-05-23 | — | — | US | claimed |
| EP-4717276-A2 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | University of Canberra (AU) | 2026-04-01 | — | — | EP | disclosed |
| EP-3442516-B1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIV CANBERRA (AU) | 2025-11-12 | — | — | EP | disclosed |
| US-11890266-B2 | Ophthalmic compositions including levodopa, an antioxidant and an aqueous carrier | UNIVERSITY OF CANBERRA (AU) | 2024-02-06 | — | — | US | disclosed |
| US-20220047529-A1 | METHODS OF INHIBITION | UNIVERSITY OF CANBERRA (AU) | 2022-02-17 | — | — | US | disclosed |
| US-20210077443-A1 | OPHTHALMIC COMPOSITIONS INCLUDING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIVERSITY OF CANBERRA (AU) | 2021-03-18 | — | — | US | disclosed |
| US-10874629-B2 | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | UNIVERSITY OF CANBERRA (AU) | 2020-12-29 | — | — | US | disclosed |
| US-20190151270-A1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIVERSITY OF CANBERRA (AU) | 2019-05-23 | — | — | US | disclosed |
| EP-0765477-A4 | RESINS FOR SOLID STATE SYNTHESIS | SMITHKLINE BEECHAM CORP (US) | 2004-11-17 | — | — | EP | disclosed |
| EP-0765477-A1 | RESINS FOR SOLID STATE SYNTHESIS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995034813-A1 | RESINS FOR SOLID STATE SYNTHESIS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047529-A1 | METHODS OF INHIBITION | SLC6A3, DBH, SNCA | GRIN2B 659/4885DRD2 5/4885DRD4 8/4885 |
| US-11890266-B2 | Ophthalmic compositions including levodopa, an antioxidant and an aqueous carrier | TTPA, TST, TXN2 | GRIN2B 2994/4885DRD2 2171/4885DRD4 2073/4885 |
| US-10874629-B2 | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | COMT, LRRK2, PARK7 | GRIN2B 1014/4885DRD2 225/4885DRD4 187/4885 |
| US-20190151270-A1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | COMT, LRRK2, PARK7 | GRIN2B 1014/4885DRD2 225/4885DRD4 187/4885 |
| US-20210077443-A1 | OPHTHALMIC COMPOSITIONS INCLUDING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | TTPA, TST, TXN2 | GRIN2B 2994/4885DRD2 2171/4885DRD4 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.